Crescent Biopharma (CBIO) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CBIO · Stock Price

USD 18.00-6.00 (-25.00%)

Market Cap: $501.5M

Historical price data

Market Cap: $501.5MFounded: 2018HQ: San Diego, United States

Sector Ranking#126 in Biologics / Biosimilars #67 in Oncology (General)

Overview

Crescent Biopharma is a public, clinical-stage biotechnology company with a mission to transform cancer treatment by capitalizing on three major paradigm shifts: next-generation immuno-oncology, improved antibody-drug conjugates (ADCs), and synergistic combination therapies. Founded in 2018 and led by a seasoned team with deep oncology development expertise, the company is advancing a pipeline of novel therapies for solid tumors. Its strategy focuses on applying validated modalities to well-characterized targets to de-risk development and accelerate the delivery of high-impact medicines.

OncologySolid Tumors

Technology Platform

An integrated strategic platform focusing on next-generation immuno-oncology bispecifics (e.g., PD-1 x VEGF), improved antibody-drug conjugates (ADCs), and rationally designed synergistic combination therapies for solid tumors.

Funding History

2

Total raised:$30M

Series A$25MUndisclosedNov 15, 2022

Seed$5MUndisclosedJun 15, 2021

Opportunities

Crescent is positioned to address large, growing markets in post-PD-1 therapies, advanced ADCs, and combination regimens.

Its de-risked strategy focusing on validated targets could lead to faster development cycles and a higher probability of clinical success, creating significant value if its candidates demonstrate best-in-class potential.

Risk Factors

The company faces high clinical development risk, intense competition in its chosen modalities, and a reliance on future capital raises that could be dilutive.

Its 'fast-follower' strategy requires flawless execution and clear differentiation to succeed in crowded fields.

Competitive Landscape

Crescent competes with large pharmaceutical companies and numerous biotechs in the bispecific antibody and ADC spaces. Its success hinges on demonstrating superior efficacy or safety profiles compared to established and emerging competitors, as it lacks a first-in-class novel mechanism.